PMC:7156291 / 14966-16098 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"278","span":{"begin":807,"end":823},"obj":"Disease"},{"id":"279","span":{"begin":860,"end":875},"obj":"Disease"}],"attributes":[{"id":"A278","pred":"tao:has_database_id","subj":"278","obj":"MESH:D010996"},{"id":"A279","pred":"tao:has_database_id","subj":"279","obj":"MESH:D008206"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Characteristic Time after disease onset χ2 p value\nDays 0–3 (n = 37) Days 4–7 (n = 69) Days 8–10 (n = 53) Days 11–14 (n = 49) Days 15–21 (n = 25)\nPulmonary opacities\n  GGO only 8 (21.6) 13 (18.8) 7 (13.2) 4 (8.2) 1 (4.0) 6.6 0.16\n  GGO and consolidation 12 (32.4) 26 (37.7) 8 (15.1) 5 (10.1) 1 (4.0) 22.2 \u003c 0.01\n  GGO and linear opacities 2 (5.4) 2 (2.9) 4 (7.5) 2 (4.1) 2 (8.0) 1.87 0.76\n  Consolidation only 1 (2.8) 6 (8.7) 3 (5.7) 4 (8.2) 1 (4.0) 1.98 0.74\n  Consolidation and linear opacities 0 (0) 2 (2.9) 4 (7.5) 4 (8.2) 3 (12.0) 6.0 0.19\n  GGO, consolidation, and linear opacities 12 (32.4) 19 (27.5) 25 (47.2) 30 (61.2) 17 (68.0) 21.5 \u003c 0.01\n  Negative CT 2 (5.4) 1 (1.5) 2 (3.8) 0 (0.0) 0 (0.0) 4.3 0.36\nOther findings\n  Discrete pulmonary nodules 4 (10.8) 4 (5.8) 3 (5.7) 1 (2.0) 0 (0) 4.8 0.36\n  Pleural effusion 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) – –\n  Lymphadenopathy 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) – –\n  Cavitation 3 (8.1) 3 (4.3) 1 (1.9) 2 (4.1) 1 (4.0) 2.1 0.72\nTotal lung severity score\n  Mean ± SD 3.9 ± 2.7 4.8 ± 2.9 4.9 ± 2.8 5.3 ± 3.3 5.2 ± 2.8 – 0.29\n  Median (range) 4 (0–10) 5 (0–12) 5 (0–11) 5 (1–13) 5 (1–11) – –"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T38","span":{"begin":978,"end":982},"obj":"Body_part"}],"attributes":[{"id":"A38","pred":"fma_id","subj":"T38","obj":"http://purl.org/sig/ont/fma/fma7195"}],"text":"Characteristic Time after disease onset χ2 p value\nDays 0–3 (n = 37) Days 4–7 (n = 69) Days 8–10 (n = 53) Days 11–14 (n = 49) Days 15–21 (n = 25)\nPulmonary opacities\n  GGO only 8 (21.6) 13 (18.8) 7 (13.2) 4 (8.2) 1 (4.0) 6.6 0.16\n  GGO and consolidation 12 (32.4) 26 (37.7) 8 (15.1) 5 (10.1) 1 (4.0) 22.2 \u003c 0.01\n  GGO and linear opacities 2 (5.4) 2 (2.9) 4 (7.5) 2 (4.1) 2 (8.0) 1.87 0.76\n  Consolidation only 1 (2.8) 6 (8.7) 3 (5.7) 4 (8.2) 1 (4.0) 1.98 0.74\n  Consolidation and linear opacities 0 (0) 2 (2.9) 4 (7.5) 4 (8.2) 3 (12.0) 6.0 0.19\n  GGO, consolidation, and linear opacities 12 (32.4) 19 (27.5) 25 (47.2) 30 (61.2) 17 (68.0) 21.5 \u003c 0.01\n  Negative CT 2 (5.4) 1 (1.5) 2 (3.8) 0 (0.0) 0 (0.0) 4.3 0.36\nOther findings\n  Discrete pulmonary nodules 4 (10.8) 4 (5.8) 3 (5.7) 1 (2.0) 0 (0) 4.8 0.36\n  Pleural effusion 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) – –\n  Lymphadenopathy 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) – –\n  Cavitation 3 (8.1) 3 (4.3) 1 (1.9) 2 (4.1) 1 (4.0) 2.1 0.72\nTotal lung severity score\n  Mean ± SD 3.9 ± 2.7 4.8 ± 2.9 4.9 ± 2.8 5.3 ± 3.3 5.2 ± 2.8 – 0.29\n  Median (range) 4 (0–10) 5 (0–12) 5 (0–11) 5 (1–13) 5 (1–11) – –"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T25","span":{"begin":807,"end":823},"obj":"Body_part"},{"id":"T26","span":{"begin":978,"end":982},"obj":"Body_part"}],"attributes":[{"id":"A25","pred":"uberon_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/UBERON_0000175"},{"id":"A26","pred":"uberon_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"}],"text":"Characteristic Time after disease onset χ2 p value\nDays 0–3 (n = 37) Days 4–7 (n = 69) Days 8–10 (n = 53) Days 11–14 (n = 49) Days 15–21 (n = 25)\nPulmonary opacities\n  GGO only 8 (21.6) 13 (18.8) 7 (13.2) 4 (8.2) 1 (4.0) 6.6 0.16\n  GGO and consolidation 12 (32.4) 26 (37.7) 8 (15.1) 5 (10.1) 1 (4.0) 22.2 \u003c 0.01\n  GGO and linear opacities 2 (5.4) 2 (2.9) 4 (7.5) 2 (4.1) 2 (8.0) 1.87 0.76\n  Consolidation only 1 (2.8) 6 (8.7) 3 (5.7) 4 (8.2) 1 (4.0) 1.98 0.74\n  Consolidation and linear opacities 0 (0) 2 (2.9) 4 (7.5) 4 (8.2) 3 (12.0) 6.0 0.19\n  GGO, consolidation, and linear opacities 12 (32.4) 19 (27.5) 25 (47.2) 30 (61.2) 17 (68.0) 21.5 \u003c 0.01\n  Negative CT 2 (5.4) 1 (1.5) 2 (3.8) 0 (0.0) 0 (0.0) 4.3 0.36\nOther findings\n  Discrete pulmonary nodules 4 (10.8) 4 (5.8) 3 (5.7) 1 (2.0) 0 (0) 4.8 0.36\n  Pleural effusion 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) – –\n  Lymphadenopathy 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) – –\n  Cavitation 3 (8.1) 3 (4.3) 1 (1.9) 2 (4.1) 1 (4.0) 2.1 0.72\nTotal lung severity score\n  Mean ± SD 3.9 ± 2.7 4.8 ± 2.9 4.9 ± 2.8 5.3 ± 3.3 5.2 ± 2.8 – 0.29\n  Median (range) 4 (0–10) 5 (0–12) 5 (0–11) 5 (1–13) 5 (1–11) – –"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T42","span":{"begin":860,"end":875},"obj":"Disease"}],"attributes":[{"id":"A42","pred":"mondo_id","subj":"T42","obj":"http://purl.obolibrary.org/obo/MONDO_0005833"}],"text":"Characteristic Time after disease onset χ2 p value\nDays 0–3 (n = 37) Days 4–7 (n = 69) Days 8–10 (n = 53) Days 11–14 (n = 49) Days 15–21 (n = 25)\nPulmonary opacities\n  GGO only 8 (21.6) 13 (18.8) 7 (13.2) 4 (8.2) 1 (4.0) 6.6 0.16\n  GGO and consolidation 12 (32.4) 26 (37.7) 8 (15.1) 5 (10.1) 1 (4.0) 22.2 \u003c 0.01\n  GGO and linear opacities 2 (5.4) 2 (2.9) 4 (7.5) 2 (4.1) 2 (8.0) 1.87 0.76\n  Consolidation only 1 (2.8) 6 (8.7) 3 (5.7) 4 (8.2) 1 (4.0) 1.98 0.74\n  Consolidation and linear opacities 0 (0) 2 (2.9) 4 (7.5) 4 (8.2) 3 (12.0) 6.0 0.19\n  GGO, consolidation, and linear opacities 12 (32.4) 19 (27.5) 25 (47.2) 30 (61.2) 17 (68.0) 21.5 \u003c 0.01\n  Negative CT 2 (5.4) 1 (1.5) 2 (3.8) 0 (0.0) 0 (0.0) 4.3 0.36\nOther findings\n  Discrete pulmonary nodules 4 (10.8) 4 (5.8) 3 (5.7) 1 (2.0) 0 (0) 4.8 0.36\n  Pleural effusion 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) – –\n  Lymphadenopathy 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) – –\n  Cavitation 3 (8.1) 3 (4.3) 1 (1.9) 2 (4.1) 1 (4.0) 2.1 0.72\nTotal lung severity score\n  Mean ± SD 3.9 ± 2.7 4.8 ± 2.9 4.9 ± 2.8 5.3 ± 3.3 5.2 ± 2.8 – 0.29\n  Median (range) 4 (0–10) 5 (0–12) 5 (0–11) 5 (1–13) 5 (1–11) – –"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T83","span":{"begin":111,"end":113},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"},{"id":"T84","span":{"begin":807,"end":823},"obj":"http://purl.obolibrary.org/obo/UBERON_0000175"},{"id":"T85","span":{"begin":978,"end":982},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T86","span":{"begin":978,"end":982},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T87","span":{"begin":1107,"end":1109},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"},{"id":"T88","span":{"begin":1125,"end":1127},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"}],"text":"Characteristic Time after disease onset χ2 p value\nDays 0–3 (n = 37) Days 4–7 (n = 69) Days 8–10 (n = 53) Days 11–14 (n = 49) Days 15–21 (n = 25)\nPulmonary opacities\n  GGO only 8 (21.6) 13 (18.8) 7 (13.2) 4 (8.2) 1 (4.0) 6.6 0.16\n  GGO and consolidation 12 (32.4) 26 (37.7) 8 (15.1) 5 (10.1) 1 (4.0) 22.2 \u003c 0.01\n  GGO and linear opacities 2 (5.4) 2 (2.9) 4 (7.5) 2 (4.1) 2 (8.0) 1.87 0.76\n  Consolidation only 1 (2.8) 6 (8.7) 3 (5.7) 4 (8.2) 1 (4.0) 1.98 0.74\n  Consolidation and linear opacities 0 (0) 2 (2.9) 4 (7.5) 4 (8.2) 3 (12.0) 6.0 0.19\n  GGO, consolidation, and linear opacities 12 (32.4) 19 (27.5) 25 (47.2) 30 (61.2) 17 (68.0) 21.5 \u003c 0.01\n  Negative CT 2 (5.4) 1 (1.5) 2 (3.8) 0 (0.0) 0 (0.0) 4.3 0.36\nOther findings\n  Discrete pulmonary nodules 4 (10.8) 4 (5.8) 3 (5.7) 1 (2.0) 0 (0) 4.8 0.36\n  Pleural effusion 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) – –\n  Lymphadenopathy 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) – –\n  Cavitation 3 (8.1) 3 (4.3) 1 (1.9) 2 (4.1) 1 (4.0) 2.1 0.72\nTotal lung severity score\n  Mean ± SD 3.9 ± 2.7 4.8 ± 2.9 4.9 ± 2.8 5.3 ± 3.3 5.2 ± 2.8 – 0.29\n  Median (range) 4 (0–10) 5 (0–12) 5 (0–11) 5 (1–13) 5 (1–11) – –"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T29","span":{"begin":1007,"end":1009},"obj":"Chemical"}],"attributes":[{"id":"A29","pred":"chebi_id","subj":"T29","obj":"http://purl.obolibrary.org/obo/CHEBI_74807"}],"text":"Characteristic Time after disease onset χ2 p value\nDays 0–3 (n = 37) Days 4–7 (n = 69) Days 8–10 (n = 53) Days 11–14 (n = 49) Days 15–21 (n = 25)\nPulmonary opacities\n  GGO only 8 (21.6) 13 (18.8) 7 (13.2) 4 (8.2) 1 (4.0) 6.6 0.16\n  GGO and consolidation 12 (32.4) 26 (37.7) 8 (15.1) 5 (10.1) 1 (4.0) 22.2 \u003c 0.01\n  GGO and linear opacities 2 (5.4) 2 (2.9) 4 (7.5) 2 (4.1) 2 (8.0) 1.87 0.76\n  Consolidation only 1 (2.8) 6 (8.7) 3 (5.7) 4 (8.2) 1 (4.0) 1.98 0.74\n  Consolidation and linear opacities 0 (0) 2 (2.9) 4 (7.5) 4 (8.2) 3 (12.0) 6.0 0.19\n  GGO, consolidation, and linear opacities 12 (32.4) 19 (27.5) 25 (47.2) 30 (61.2) 17 (68.0) 21.5 \u003c 0.01\n  Negative CT 2 (5.4) 1 (1.5) 2 (3.8) 0 (0.0) 0 (0.0) 4.3 0.36\nOther findings\n  Discrete pulmonary nodules 4 (10.8) 4 (5.8) 3 (5.7) 1 (2.0) 0 (0) 4.8 0.36\n  Pleural effusion 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) – –\n  Lymphadenopathy 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) – –\n  Cavitation 3 (8.1) 3 (4.3) 1 (1.9) 2 (4.1) 1 (4.0) 2.1 0.72\nTotal lung severity score\n  Mean ± SD 3.9 ± 2.7 4.8 ± 2.9 4.9 ± 2.8 5.3 ± 3.3 5.2 ± 2.8 – 0.29\n  Median (range) 4 (0–10) 5 (0–12) 5 (0–11) 5 (1–13) 5 (1–11) – –"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T35","span":{"begin":146,"end":165},"obj":"Phenotype"},{"id":"T36","span":{"begin":807,"end":823},"obj":"Phenotype"},{"id":"T37","span":{"begin":860,"end":875},"obj":"Phenotype"}],"attributes":[{"id":"A35","pred":"hp_id","subj":"T35","obj":"http://purl.obolibrary.org/obo/HP_0031457"},{"id":"A36","pred":"hp_id","subj":"T36","obj":"http://purl.obolibrary.org/obo/HP_0002202"},{"id":"A37","pred":"hp_id","subj":"T37","obj":"http://purl.obolibrary.org/obo/HP_0002716"}],"text":"Characteristic Time after disease onset χ2 p value\nDays 0–3 (n = 37) Days 4–7 (n = 69) Days 8–10 (n = 53) Days 11–14 (n = 49) Days 15–21 (n = 25)\nPulmonary opacities\n  GGO only 8 (21.6) 13 (18.8) 7 (13.2) 4 (8.2) 1 (4.0) 6.6 0.16\n  GGO and consolidation 12 (32.4) 26 (37.7) 8 (15.1) 5 (10.1) 1 (4.0) 22.2 \u003c 0.01\n  GGO and linear opacities 2 (5.4) 2 (2.9) 4 (7.5) 2 (4.1) 2 (8.0) 1.87 0.76\n  Consolidation only 1 (2.8) 6 (8.7) 3 (5.7) 4 (8.2) 1 (4.0) 1.98 0.74\n  Consolidation and linear opacities 0 (0) 2 (2.9) 4 (7.5) 4 (8.2) 3 (12.0) 6.0 0.19\n  GGO, consolidation, and linear opacities 12 (32.4) 19 (27.5) 25 (47.2) 30 (61.2) 17 (68.0) 21.5 \u003c 0.01\n  Negative CT 2 (5.4) 1 (1.5) 2 (3.8) 0 (0.0) 0 (0.0) 4.3 0.36\nOther findings\n  Discrete pulmonary nodules 4 (10.8) 4 (5.8) 3 (5.7) 1 (2.0) 0 (0) 4.8 0.36\n  Pleural effusion 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) – –\n  Lymphadenopathy 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) – –\n  Cavitation 3 (8.1) 3 (4.3) 1 (1.9) 2 (4.1) 1 (4.0) 2.1 0.72\nTotal lung severity score\n  Mean ± SD 3.9 ± 2.7 4.8 ± 2.9 4.9 ± 2.8 5.3 ± 3.3 5.2 ± 2.8 – 0.29\n  Median (range) 4 (0–10) 5 (0–12) 5 (0–11) 5 (1–13) 5 (1–11) – –"}

{"project":"LitCovid-sentences","denotations":[{"id":"T148","span":{"begin":0,"end":50},"obj":"Sentence"},{"id":"T149","span":{"begin":51,"end":145},"obj":"Sentence"},{"id":"T150","span":{"begin":146,"end":165},"obj":"Sentence"},{"id":"T151","span":{"begin":166,"end":229},"obj":"Sentence"},{"id":"T152","span":{"begin":230,"end":311},"obj":"Sentence"},{"id":"T153","span":{"begin":312,"end":388},"obj":"Sentence"},{"id":"T154","span":{"begin":389,"end":459},"obj":"Sentence"},{"id":"T155","span":{"begin":460,"end":544},"obj":"Sentence"},{"id":"T156","span":{"begin":545,"end":649},"obj":"Sentence"},{"id":"T157","span":{"begin":650,"end":712},"obj":"Sentence"},{"id":"T158","span":{"begin":713,"end":727},"obj":"Sentence"},{"id":"T159","span":{"begin":728,"end":804},"obj":"Sentence"},{"id":"T160","span":{"begin":805,"end":857},"obj":"Sentence"},{"id":"T161","span":{"begin":858,"end":909},"obj":"Sentence"},{"id":"T162","span":{"begin":910,"end":971},"obj":"Sentence"},{"id":"T163","span":{"begin":972,"end":997},"obj":"Sentence"},{"id":"T164","span":{"begin":998,"end":1066},"obj":"Sentence"},{"id":"T165","span":{"begin":1067,"end":1132},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Characteristic Time after disease onset χ2 p value\nDays 0–3 (n = 37) Days 4–7 (n = 69) Days 8–10 (n = 53) Days 11–14 (n = 49) Days 15–21 (n = 25)\nPulmonary opacities\n  GGO only 8 (21.6) 13 (18.8) 7 (13.2) 4 (8.2) 1 (4.0) 6.6 0.16\n  GGO and consolidation 12 (32.4) 26 (37.7) 8 (15.1) 5 (10.1) 1 (4.0) 22.2 \u003c 0.01\n  GGO and linear opacities 2 (5.4) 2 (2.9) 4 (7.5) 2 (4.1) 2 (8.0) 1.87 0.76\n  Consolidation only 1 (2.8) 6 (8.7) 3 (5.7) 4 (8.2) 1 (4.0) 1.98 0.74\n  Consolidation and linear opacities 0 (0) 2 (2.9) 4 (7.5) 4 (8.2) 3 (12.0) 6.0 0.19\n  GGO, consolidation, and linear opacities 12 (32.4) 19 (27.5) 25 (47.2) 30 (61.2) 17 (68.0) 21.5 \u003c 0.01\n  Negative CT 2 (5.4) 1 (1.5) 2 (3.8) 0 (0.0) 0 (0.0) 4.3 0.36\nOther findings\n  Discrete pulmonary nodules 4 (10.8) 4 (5.8) 3 (5.7) 1 (2.0) 0 (0) 4.8 0.36\n  Pleural effusion 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) – –\n  Lymphadenopathy 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) – –\n  Cavitation 3 (8.1) 3 (4.3) 1 (1.9) 2 (4.1) 1 (4.0) 2.1 0.72\nTotal lung severity score\n  Mean ± SD 3.9 ± 2.7 4.8 ± 2.9 4.9 ± 2.8 5.3 ± 3.3 5.2 ± 2.8 – 0.29\n  Median (range) 4 (0–10) 5 (0–12) 5 (0–11) 5 (1–13) 5 (1–11) – –"}